Neramexane Merz Pharmaceuticals/Forest Laboratories

Gerhard Rammes, Anja Schierloh

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Merz Pharmaceuticals GmbH and Forest Laboratories Inc are developing neramexane, an oral N-methyl-D-aspartate antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.

Original languageEnglish
Pages (from-to)128-135
Number of pages8
JournalIDrugs
Volume9
Issue number2
StatePublished - Feb 2006

Fingerprint

Dive into the research topics of 'Neramexane Merz Pharmaceuticals/Forest Laboratories'. Together they form a unique fingerprint.

Cite this